Literature DB >> 15168457

[A case of eosinophilic pneumonia possibly associated with 5-aminosalicylic acid (5-ASA)].

Yusuke Hakoda1, Masahiro Aoshima, Masao Kinoshita, Michio Sakurai, Kazuma Ohyashiki.   

Abstract

A 30-year-old man was diagnosed as having ulcerative colitis and was treated with 2,250 mg/day of 5-aminosalicylic acid (5-ASA). After 4 weeks of the administration, the patient complained of cough and fever and was admitted to our hospital. His chest radiograph showed infiltrative shadows bilaterally in the lung fields. Peripheral blood analysis indicated eosinophilia. We confirmed eosinophilic pneumonia by bronchoalveolar lavage and transbronchial lung biopsy. Improvement in clinical symptoms and radiological findings was obtained after the cessation of 5-ASA and initiation of prednisolone. Finally, mesalazine-induced eosinophilic pneumonia was diagnosed on the basis of his clinical course. The literature contains a few reports on patients with mesalazine-induced eosinophilic pneumonia.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15168457

Source DB:  PubMed          Journal:  Nihon Kokyuki Gakkai Zasshi        ISSN: 1343-3490


  3 in total

1.  Gastroenterology case report of mesalazine-induced cardiopulmonary hypersensitivity.

Authors:  José Ferrusquía; Isabel Pérez-Martínez; Ricardo Gómez de la Torre; María Luisa Fernández-Almira; Ruth de Francisco; Luis Rodrigo; Sabino Riestra
Journal:  World J Gastroenterol       Date:  2015-04-07       Impact factor: 5.742

2.  Mesalazine-induced eosinophilic pneumonia with bone marrow infiltration: a case report and literature review.

Authors:  Yunjian Zhang; Ling Luo; Xiaofang Wang; Xiaoyang Liu; Xiaoyan Wang; Yi Ding
Journal:  Ther Clin Risk Manag       Date:  2016-06-14       Impact factor: 2.423

3.  Mesalazine-induced lung injury with severe respiratory failure successfully treated with steroids and non-invasive positive pressure ventilation.

Authors:  Hajime Oi; Atsushi Suzuki; Yasuhiko Yamano; Toshiki Yokoyama; Toshiaki Matsuda; Kensuke Kataoka; Yasuhiko Suzuki; Tomoki Kimura; Yasuhiro Kondoh
Journal:  Respir Med Case Rep       Date:  2020-08-03
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.